Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088043 · ClinicalTrials.gov registry record · Phase 3
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 693
- Enrollment target
NCT06088043 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 693 participants.
The verdict
NCT06088043, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 693 participants
- Enrollment target
Study Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.
Interventions
- DRUG Placebo
- DRUG TAK-279
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 693 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2025-10-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06088043
The ClinicalTrials.gov registry entry for NCT06088043 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 693 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06088043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06088043 about?
NCT06088043 is a clinical study titled "A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment". The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will...
What is the current status of trial NCT06088043?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 693 participants. The study started on 2023-11-06. Estimated completion is 2025-10-22.
What interventions are being tested in trial NCT06088043?
The interventions under investigation include: Placebo (DRUG), TAK-279 (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT06088043?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.